Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: data from the PROWESS trial
Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: data from the PROWESS trial. Intensive Care Medicine. 2003;29:894–903.
This study finds that drotrecogin alfa (activated) therapy reduces 28-day mortality and speeds recovery of cardiovascular and respiratory organ function. The increased risk of bleeding associated with this therapy appears to be outweighed by treatment benefits.
Rated by Users: 
|
 |
View article abstract
|
